A Cystic Fibrosis Bronchial Epithelial Cell Line (CF8Flp)
JHU REF: C12966
Invention Novelty:
The invention is in the form of a Cystic Fibrosis Bronchial Epithelial Cell Line with an integration site that allows for stable expression of the target protein.
Value Proposition:
Bronchial epithelial cells have been particularly instrumental in providing a means to more fully characterize the relationship between the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene and disease phenotype. In addition, these cells have been critical in the development of genetic and pharmacological therapies and are important for high-through-put screening strategies now being employed to identify new drugs for the treatment of Cystic Fibrosis. Most of the cell lines available today are transient cell lines that cannot express uniform levels of CFTR gene, which caps their use to a large extent. This technology circumvents this limitation and enables
- Uniform expression of the target protein ‘
- Improved reliability
- Greater efficiency
- Enables reproducibility of assay results
Technical Details:
Researchers at Johns Hopkins University have developed a Cystic Fibrosis Bronchial Epithelial Cell that has a recombinase target site integrated in the genome of the bronchial epithelial cells that enables uniform expression of the desired protein.
Looking for Partners:
To develop and commercialize the technology as a research tool for understanding the disease and for drug discovery purposes.
Stage of Development: Ready for commercial use
Patent Status: None, Tangible material
Publication(s)/Associated Cases: J Cyst Fibros. 2016 May; 15(3): 285–294.
